TrialMedicine2019

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.

Qian Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.